The landscape for patenting AI technologies in drug discovery is being shaped by new regulations and case law, impacting how companies approach IP protection and litigation. This session will detail the evolving challenges and opportunities in patenting AI-assisted drug discovery innovations, considering recent legal and regulatory developments in Europe and the U.S. Points of discussion will include:

• Exploring the impact of the European Union’s AI Act, the first comprehensive AI law, on AI in drug discovery
• Examining the increasing trend of patent filings related to AI and machine learning in drug discovery
• Developing strategies for patenting AI innovations, including the challenges of meeting patentability criteria like novelty and non-obviousness
• Analyzing the importance of data exclusivity in AI-driven drug discovery, focusing on strategies for protecting proprietary data and the implications for patent enforcement
• Addressing the challenges of managing IP for AI-assisted drug discovery in a global context, taking into account different regulatory environments and the need for harmonized strategies